Pfizer’s quarterly profit beat market estimates, partly helped by higher-than-expected sales of its blockbuster pneumonia vaccine, Prevnar. The company also raised its full-year earnings forecast.

Pfizer’s revenue shortfall in the last quarter is reigniting pressure on the New York drugmaker to make deals to return to growth.

Bayer has forecast 8% annual growth in pharmaceutical revenue through 2016 on demand for new medicines.